Related Experiment Videos
Clinical findings and prognostic factors in chronic myeloid leukemias
Insights
This study on chronic myeloid leukemia (CML) found that Philadelphia chromosome-positive patients had a median survival of 38 months. Low hemoglobin and high blast counts indicated a poor prognosis in this CML group.
Area of Science:
- Hematology
- Oncology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- The Philadelphia chromosome (Ph1) is a hallmark genetic abnormality in CML.
Purpose of the Study:
- To investigate prognostic factors and survival outcomes in previously untreated chronic myeloid leukemia patients.
- To evaluate the impact of early splenectomy on survival in Ph1-positive CML.
Main Methods:
- Retrospective analysis of 91 previously untreated CML patients.
- Data collection on clinical characteristics, laboratory values, and survival.
- Comparison of outcomes between Ph1-positive and Ph1-negative CML groups.
Main Results:
- Median survival was 38 months for Ph1-positive vs. 12 months for Ph1-negative CML.
- Low hemoglobin and high blast cell count at diagnosis predicted poor prognosis in Ph1-positive CML.
- Early splenectomy did not improve survival in 15 Ph1-positive patients.
Conclusions:
- Prognosis in CML is significantly influenced by Philadelphia chromosome status.
- Specific clinical factors like hemoglobin and blast count are critical for predicting outcomes in Ph1-positive CML.
- Current evidence does not support early splenectomy as a survival-enhancing intervention for CML.
Abstract:
Ninety-one previously untreated patients with chronic myeloid leukemia admitted to three Stockholm hospitals 1973-1978 were studied. There were 49 men and 42 women with a mean age of 56 years (range 15-93). Sixty-five patients were Philadelphia chromosome (Ph1) positive and 17 were Ph1 negative (mean age 51 and 70 years, respectively). After a mean observation time of 5.2 years, 64 patients had deceased, 45 of them in blast transformation. A low hemoglobin value and a high total blast cell count at diagnosis were associated with a poor prognosis in the Ph1 positive group. Other routine clinical and laboratory variables were of subordinate prognostic importance. Early splenectomy in 15 Ph1 positive patients did not improve survival. Median survival from diagnosis was 38 months for Ph1 positive patients as compared to 12 months for the Ph1 negative group.